Naphthyridines as inhibitors of HPK1

US11034692B1 · kind B1 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Bryan Chan · South San Francisco, US
• Blake Daniels · South San Francisco, US
• Joy Drobnick · South San Francisco, US
• Lewis Gazzard · Belmont, US
• Timothy Heffron · Burlingame, US
• Malcolm Huestis · South San Francisco, US
• Jun Liang · Los Altos Hills, US
• Sushant Malhotra · South San Francisco, US
• Rohan Mendonca · South San Francisco, US
• Naomi Rajapaksa · San Mateo, US
• Michael Siu · Burlingame, US
• Craig Stivala · San Mateo, US
• John Tellis · San Mateo, US
• Weiru Wang · Lafayette, US
• BinQing Wei · Belmont, US
• Aihe Zhou · San Jose, US
• Matthew W. Cartwright · Harlow, GB
• Emanuela Gancia · Harlow, GB
• Graham Elgin Jones · Harlow, GB
• Michael Lainchbury · Harlow, GB
• Andrew Madin · Hertford, GB
• Eileen Mary Seward · Bishop's Stortford, GB
• David Favor · Shanghai, CN
• Kin Chiu Fong · Shanghai, CN
• Andrew C. Good · Wallingford, US
• Yonghan Hu · Shanghai, CN
• Baihua Hu · Audubon, US
• Aijun Lu · Beijing, CN

Key dates

• Filing date: Aug 15, 2019
• Grant date: Jun 15, 2021
• Expiry date: Aug 15, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.